Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery

RATIONALE: Uncertainty regarding the natural history of coronavirus disease (COVID-19) led to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur after hospital discharge may improve assessment of clinical recovery among hospitalized patients with COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Douin, David J., Siegel, Lianne, Grandits, Greg, Phillips, Andrew, Aggarwal, Neil R., Baker, Jason, Brown, Samuel M., Chang, Christina C., Goodman, Anna L., Grund, Birgit, Higgs, Elizabeth S., Hough, Catherine L., Murray, Daniel D., Paredes, Roger, Parmar, Mahesh, Pett, Sarah, Polizzotto, Mark N., Sandkovsky, Uriel, Self, Wesley H., Young, Barnaby E., Babiker, Abdel G., Davey, Victoria J., Kan, Virginia, Gelijns, Annetine C., Matthews, Gail, Thompson, B. Taylor, Lane, H. Clifford, Neaton, James D., Lundgren, Jens D., Ginde, Adit A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Thoracic Society 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799123/
https://www.ncbi.nlm.nih.gov/pubmed/35580040
http://dx.doi.org/10.1164/rccm.202112-2836OC

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799123/
https://www.ncbi.nlm.nih.gov/pubmed/35580040
http://dx.doi.org/10.1164/rccm.202112-2836OC

Ejemplares similares